Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | AZD9496 |
| Synonyms | |
| Therapy Description |
AZD9496 is a selective degrader of estrogen receptor, which leads to growth inhibition of ER-positive tumors (PMID: 32609836, PMID: 32461092, PMID: 32234755). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| AZD9496 | AZD-9496|AZD 9496 | Hormone - Anti-estrogens 31 | AZD9496 is a selective degrader of estrogen receptor, which leads to growth inhibition of ER-positive tumors (PMID: 32609836, PMID: 32461092, PMID: 32234755). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT02780713 | Phase I | AZD9496 | A Study to Assess the Pharmacokinetics and Safety of Different Forms and Formulations of AZD9496 in Healthy Subjects (PK) | Completed | USA | 0 |
| NCT02248090 | Phase I | AZD9496 | AZD9496 First Time in Patients Ascending Dose Study | Completed | USA | GBR | 1 |